@Hadrian
The key point is that the very purpose of generics is to circumvent the high prices of branded product, which are caused by the dysfunctional incentives of the middle-men. So what sense would it make to have them held hostage to those channels? More to the point, what incentive would those middle-men have to push low priced generics?
Ann: Launch of Dapsone 5%, Gel in the United States, page-26
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.6¢ |
Change
-0.001(1.49%) |
Mkt cap ! $19.18M | |||
| Open | High | Low | Value | Volume |
| 6.7¢ | 6.7¢ | 6.6¢ | $17.36K | 261.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 88067 | 6.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.7¢ | 2000 | 1 |
View Market Depth
| Last trade - 15.48pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.6¢ |
Change
-0.001 ( 1.49 %) |
||||
| Open | High | Low | Volume | ||
| 6.7¢ | 6.7¢ | 6.6¢ | 33642 | ||
| Last updated 15.20pm 22/05/2024 ? | |||||
| ACR (ASX) Chart |